Company intelligence / Profile preview
RoC
Suzhou, Jiangsu, Chinarocrockbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead program RR-M01 in clinical trials as of 2024, has completed drug administration assessment for multiple subjects with good safety and efficacy signals. Focused on malignant solid tumors including ovarian cancer, expanding indications to all HER2-positive or low-expression solid tumors. Additional clinical trials ongoing/planned for pancreatic/prostate/small cell lung cancers.
- Therapeutic areas
- OncologyRare Diseases
- Modalities
- Cell therapyGene editing
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Affiliated Hospital of Xuzhou Medical University (clinical trial partner)International collaboration with Armenia on rare disease research
Beyond the preview
Go deeper on RoC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RoC.